Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

6. Tobacco 135Orleans, C. T. (1993). Treating nicotine dependence in medical settings: A steppedcare model. In C. T. Orleans & J. Slade (Eds.), Nicotine addiction: Principles andmanagement (pp. 145–161). New York: Oxford University Press.Pharmacists’ “Helping Smokers Quit” Program. (1986). Am Pharm, NS26, 25–33.Pierce, J. P., & Gilpin, E. A. (1996). How long will today’s new adolescent smoker beaddicted to cigarettes? Am J Public Health, 86, 253–256.Pierce, J. P., & Gilpin, E. A. (2002). Impact of over-the-counter sales on effectivenessof pharmaceutical aids for smoking cessation. JAMA, 288, 1260–1264.Rigotti, N. A., Lee, J. E., & Wechsler, H. (2000). U.S. college students use of cigarettes,cigars, pipes, and smokeless tobacco. JAMA, 284, 699–705.Sachs, D. P. L. (1986). Nicotine polacrilex: Clinical promises delivered and yet tocome. In J. K. Ockene (Ed.), The pharmacologic treatment of tobacco dependence:Proceedings of the World Congress (pp. 120–140). Cambridge, MA: Institute for theStudy of Smoking Behavior and Policy.Samet, J. M. (2001). The risks of active and passive smoking. In P. Slovic (Ed.),Smoking, risk, perception, and policy (pp. 3–28). Thousand Oaks, CA: Sage.Sargent, J. D., Dalton, M., Beach, M., Bernhardt, A., Heatherton, T., & Stevens, M.(2000). Effect of cigarette promotions on smoking uptake among adolescents. PrevMed, 30, 320–327.Schachter, S. (1982). Recidivism and self-cure of smoking and obesity. Am Psychol, 37,436–444.Schultes, R. E. (1978). Ethnopharmacological significance of psychotropic drugs of vegetalorigin. In W. G. Clark & J. del Giudice (Eds.), Principles of psychopharmacology(pp. 41–70). New York: Academic Press.Schwartz, J. L. (1987). Smoking cessation methods: The United States and Canada, 1978–1985 (DHHS Publication No. NIH 87-2940). Washington, DC: U.S. GovernmentPrinting Office.Seely, J. E., Zuskin, E., & Bouhuys, A. (1971). Cigarette smoking: Objective evidencefor lung damage in teen-agers. Science, 172, 741–743.Shiffman, S. (1986). A cluster-analytic typology of smoking relapse episodes. AddictBehav, 11, 295–307.Shiffman, S., Dresler, C. M., Hajek, P., Gilburt, S. J., Targett, D. A., & Strahs, K. R.(2002). Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med, 162,1267–1276.Shiffman, S., Gitchell, J., Pinney, J. M., Burton, S. L., Kemper, K. E., & Lara, E. A.(1997). Public health benefit of over-the-counter nicotine medications. Tob Control,6, 306–310.Sims, T. H. & Fiore, M. C. (2002). Pharmacotherapy for treating tobacco dependence:What is the ideal duration of therapy? CNS Drugs, 16, 653–662.Slade, J., Connolly, G. N., & Lymperis, D. (2002). Eclipse: Does it live up to its healthclaims? Tob Control, 11, 64–70.Sullivan, L. W. (1991). To thwart the tobacco companies. JAMA, 266, 2131.Sussman, S., Dent, C. W., & Lichtman, K. (2000). Project EX outcomes of a teen smokingcessation program. Addict Behav, 25, 1–14.Sussman, S., Lichtman, K., Ritt, A., & Pallonen, U. E. (1999). Effects of thirty-fouradolescent tobacco use cessation and prevention trials on regular users of tobaccoproducts. Subst Use Misuse, 34, 1469–1503.